Anti-GOLGA2 (GM130) Antibody

Our Anti-GOLGA2 (GM130) chicken polyclonal primary antibody from Aves Labs is produced in-house. It detects human GOLGA2 (GM130), and is affinity-purified IgY. It is great for use in IHC, ICC, WB.

Product Specifications

Background

GOLGA2, also known as GM130, is a Golgi matrix protein critical for the proper functioning and organization of the Golgi apparatus. Discovered in the mid-1990s, GOLGA2 is involved in the maintenance of Golgi structure and the facilitation of vesicle trafficking within the cell. This protein is pivotal in ensuring that proteins and lipids are correctly modified, sorted, and sent to their destined locations, which is essential for various cellular processes including secretion, plasma membrane repair, and lysosome function. GOLGA2's role in cellular homeostasis and its effect on the Golgi apparatus associates it with several neurodegenerative and congenital disorders. Mutations in the gene and dysfunction of the protein can lead to brain development delays, and diseases such as Parkinson’s and ALS (Huang et al. 2021) . Also, changes in GOLGA2 levels can affect Golgi structure and vesicle trafficking leading to aberrant cell proliferation, tumorigenesis and metastasis, making GOLGA2 a target of anti-cancer gene therapy (Chang et al. 2012) .

Short Description

Our Anti-GOLGA2 (GM130) chicken polyclonal primary antibody from Aves Labs is produced in-house. It detects human GOLGA2 (GM130), and is affinity-purified IgY. It is great for use in IHC, ICC, WB.

Synonyms

Golgin A2, Golgin-95, GM130, Golgi Autoantigen, Golgin Subfamily A, 2, 130 KDa Cis-Golgi Matrix Protein, SY11 Protein, DEDHMB

Other Statements

These antibodies are to be used as research laboratory reagents and are not for use as diagnostic or therapeutic reagents in humans.

Gene Name

GOLGA2

Host

Chicken

Species Reactivity

Human

Reactivity

Human

Immunogen

Synthetic peptide

Immunogen Type

Human

Target

GM130

Clonality

Polyclonal

Isotype

IgY

Conjugation

Unconjugated

Applications

ICC, IHC, WB

Field of Research

Neurodegenerative Disease Parkinson's Disease Amyotrophic Lateral Sclerosis (ALS) Oncoproteins Vesicle Trafficking/Fusion

Assay Type

Primary Antibody

Assay Protocol

Eggs from hens hyperimmunized with target were used to prepare an IgY fraction which was then subjected to antigen-specific affinity purification

Concentration

200 µg/mL

Format

Affinity-Purified IgY

Form

Affinity-Purified IgY

Buffer

Phosphate-buffered (10 mM) isotonic (0.9%, w/v) saline (“PBS, " pH 7.2) with sodium azide (0.02%, w/v) added as a preservative.

Molecular Weight

130 kDa

Precautions

These antibodies are to be used as research laboratory reagents and are not for use as diagnostic or therapeutic reagents in humans.

Shipping Conditions

Ice Packs

Storage Conditions

Store at 4°C in the dark. Under these conditions, the antibodies should have a shelf life of at least twelve months, provided they remain sterile. For longer term storage, aliquot and freeze to avoid freeze-thaw of the antibody.

Shelf Life

12 months from receipt of product

IHC Dilution

1:100-1:500

WB Dilution

1:500-1:2000

Specificity

No cross-reactivity reported

Pre Treatment

Eggs from hens hyperimmunized with target were used to prepare an IgY fraction which was then subjected to antigen-specific affinity purification

Target Description

GOLGA2, also known as GM130, is a Golgi matrix protein critical for the proper functioning and organization of the Golgi apparatus. Discovered in the mid-1990s, GOLGA2 is involved in the maintenance of Golgi structure and the facilitation of vesicle trafficking within the cell. This protein is pivotal in ensuring that proteins and lipids are correctly modified, sorted, and sent to their destined locations, which is essential for various cellular processes including secretion, plasma membrane repair, and lysosome function. GOLGA2's role in cellular homeostasis and its effect on the Golgi apparatus associates it with several neurodegenerative and congenital disorders. Mutations in the gene and dysfunction of the protein can lead to brain development delays, and diseases such as Parkinson’s and ALS (Huang et al. 2021). Also, changes in GOLGA2 levels can affect Golgi structure and vesicle trafficking leading to aberrant cell proliferation, tumorigenesis and metastasis, making GOLGA2 a target of anti-cancer gene therapy (Chang et al. 2012).

ICC Dilution

1:100-1:500

Quality Control

Each new lot of this antibody is tested to confirm that it recognizes a single immunoreactive band of expected molecular weight when used to probe HeLa cell lysate.